• Skip to main content

Parkinson’s Treatment Report

www.ParkinsonsTreatmentReport.com

SER-214

A Study of Weekly Subcutaneous Injections of SER-214 in Subjects With Parkinson’s Disease (PD), to Determine the Safety, Tolerability and Pharmacokinetic (PK) Profile of SER-214

September 18, 2019

https://clinicaltrials.gov/ct2/show/NCT02579473?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=09%2F04%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
A Study of Weekly Subcutaneous Injections of SER-214 in Subjects With Parkinson’s Disease (PD), to Determine the Safety, Tolerability and Pharmacokinetic (PK) Profile of SER-214

DESCRIPTION:
Condition:   Parkinson’s Disease
Intervention:   Drug: SER-214
Sponsor:   Serina Therapeutics
Active, not recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT02579473

FIRST POSTED:
Mon, 19 Oct 2015 12:00:00 EDT

LAST UPDATE POSTED:
09/18/19 07:46AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT02579473?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=09%2F04%2F2019&lupd_d=14&sort=nwst

Powered by Urgent Research

Copyright © 2025 Urgent Research